Life Sciences

Enabling innovation for science, technology and research.

Life science facilities demand exceptional M&E precision. We design and install to the highest levels of compliance across the full spectrum of complex environments, from cleanrooms and GMP manufacturing spaces to CL3 containment laboratories and proton beam therapy centres. 

Our process is shaped by the highly regulatory nature of the sector. We embed our teams early alongside clients, specialist consultants and validation partners to ensure all requirements and environmental controls are designed in from the outset. Our specialist supply chain and digital capability across pharmaceutical and biotech environments means every system we deliver is fully compliant from day one. 

Our experience spans the breadth of this sector – working alongside leading pharma manufacturers and world class research institutions, we’ve developed long-term relationships based on trust and a consistent track record of deliveryAs science and technology continue to evolve, so too does our capability to engineer the infrastructure that supports them. 

Key Stats

Largest single life science project​:

£50m

Number of Projects delivered: 

5+

Total value of life science projects delivered: 

£116m+

Longest M&E project: 

21 months

Key Trends

As life sciences expand in scale and ambition, infrastructure must adapt accordingly. Driven by the growing needs of ageing populations, significant investment is flowing into new facilities, innovation hubs, and R&D campuses, while existing infrastructure faces growing pressure to meet increasingly stringent regulatory demands. 

M&E systems are foundational and sit at the heart of every life sciences facility, providing the infrastructure that cleanrooms, environmental controls, and production spaces depend on to operate safely and efficiently. 

We see the following as fundamental drivers shaping the future of life sciences infrastructure and the increasing complexity of M&E requirements: 

The growth of start-ups, spin-outs, and early-stage biotech companies is reshaping how life science space is occupied and used, creating demand for shared, flexible environments that lower the barrier to entry for emerging research businesses. 

The growth of start-ups, spin-outs, and early-stage biotech companies is reshaping how life science space is occupied and used, creating demand for shared, flexible environments that lower the barrier to entry for emerging research businesses.